Targeting the loss of the von Hippel-Lindau tumor suppressor gene in renal cell carcinoma cells.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Cancer Research

• Publication date

  2007-06-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-07-0604PMID 17575159
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer Statistics, 2007

  2007cited by this paper
• Reversing Hypoxic Cell Chemoresistance in Vitro Using Genetic and Small Molecule Approaches Targeting Hypoxia Inducible Factor-1

  2006cited by this paper
• Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

  2006cited by this paper
• Renal cell carcinoma risk in type 2 von Hippel-Lindau disease correlates with defects in pVHL stability and HIF-1alpha interactions.

  2006cited by this paper
• Renal cell carcinoma risk in type 2 von Hippel–Lindau disease correlates with defects in pVHL stability and HIF-1α interactions

  2006cited by this paper
• Identification of novel small molecule inhibitors of hypoxia-inducible factor-1 that differentially block hypoxia-inducible factor-1 activity and hypoxia-inducible factor-1alpha induction in response to hypoxic stress and growth factors.

  2005cited by this paper
• The Concept of Synthetic Lethality in the Context of Anticancer Therapy

  2005cited by this paper
• Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway.

  2005cited by this paper
• Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity.

  2005cited by this paper
• Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway.

  2004cited by this paper
• Dead Cells Don’t Form Tumors: HIF-Dependent Cytotoxins

  2004cited by this paper
• Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors.

  2004cited by this paper
• Role of VHL gene mutation in human cancer.

  2004cited by this paper
• Inhibition of HIF2α Is Sufficient to Suppress pVHL-Defective Tumor Growth

  2003cited by this paper
• Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells.

  2003cited by this paper
• HIF-1 as a target for drug development

  2003cited by this paper
• The hypoxic response of tumors is dependent on their microenvironment.

  2003cited by this paper
• Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas.

  2003cited by this paper
• The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis.

  2003cited by this paper
• Role of Prolyl Hydroxylation in Oncogenically Stabilized Hypoxia-inducible Factor-1α*

  2002cited by this paper
• Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein.

  2002cited by this paper
• Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway.

  2002cited by this paper
• Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation

  2001cited by this paper
• Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease.

  2001cited by this paper
• HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O2 Sensing

  2001cited by this paper
• Systematic variation in gene expression patterns in human cancer cell lines

  2000cited by this paper
• The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis

  1999cited by this paper
• Tumour suppression by the human von Hippel-Lindau gene product

  1995influential reference
• Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen

  1995cited by this paper
• Mutations of the VHL tumour suppressor gene in renal carcinoma

  1994cited by this paper
• Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm.

  1989cited by this paper
• Chromomycin A 3 , an antitumor antibiotic: tissue distribution studies in mice as measured by microbial assay.

  1971cited by this paper
• Chromomycin A3, an Antitumor Antibiotic: Tissue Distribution Studies in Mice as Measured by Microbial Assay

  1971cited by this paper

• Genetic approaches to understand cellular responses to oxygen availability

  2021cites this paper
• The m6A RNA demethylase FTO is a HIF-independent synthetic lethal partner with the VHL tumor suppressor

  2020cites this paper
• EU-OPENSCREEN: A Novel Collaborative Approach to Facilitate Chemical Biology

  2019cites this paper
• Discovery of a novel 2,5-dihydroxycinnamic acid-based 5-lipoxygenase inhibitor that induces apoptosis and may impair autophagic flux in RCC4 renal cancer cells.

  2019cites this paper
• Targeting the Mevalonate Pathway Suppresses VHL-Deficient CC-RCC through an HIF-Dependent Mechanism

  2018cites this paper
• VHL and Hypoxia Signaling: Beyond HIF in Cancer

  2018cites this paper
• is with in

  2017cites this paper
• A Patent Review on Thiazole Derivatives (2008-2013)

  2017cites this paper
• Association of genetic variations in RTN4 3′-UTR with risk for clear cell renal cell carcinoma

  2017cites this paper
• Quantitative proteomics to study a small molecule targeting the loss of von Hippel–Lindau in renal cell carcinomas

  2017cites this paper
• Rho-Associated Kinase 1 (ROCK1) inhibition is Synthetically Lethal with Von Hippel Lindau (VHL) Deficiency in Clear Cell Renal Cell Carcinoma (CC-RCC)

  2016cites this paper
• Hypoxia-directed drug strategies to target the tumor microenvironment.

  2014cites this paper
• Inhibiteurs du transporteur slc2a

  2014cites this paper
• Molecular pathology of Birt-Hogg-Dubé Syndrome

  2014influential citation
• Small Molecules Targeting the VHL/Hypoxic Phenotype

  2014cites this paper
• Identifying novel targets in renal cell carcinoma: design and synthesis of affinity chromatography reagents.

  2014cites this paper
• HCS strategy targeting dysregulation of the VHL/HIF pathway for drug discovery *

  2013cites this paper
• Exploring Novel Opportunities for Aureolic Acids as Anticancer Drugs

  2013cites this paper
• Exploring Novel Opportunities for Aureolic Acids as Anticancer Drugs

  2013cites this paper
• Antisense Technology: From Unique Laboratory Tool to Novel Anticancer Treatments

  2012cites this paper
• Radiosensitization of renal cell carcinoma in vitro through the induction of autophagy.

  2012cites this paper
• Novel approaches in the synthesis of batracylin and its analogs: rebirth of an old player?

  2012cites this paper
• Preclinical Development Therapeutic Targeting the Loss of the Birt-Hogg-Dub e Suppressor Gene

  2011influential citation
• Therapeutic Targeting the Loss of the Birt-Hogg-Dubé Suppressor Gene

  2011influential citation
• Chan Chemical Synthetic Lethality Targeting GLUT 1 and the Warburg Effect in Renal Cell Carcinoma by

  2011cites this paper
• Suppressor Gene Therapeutic Targeting the Loss of the Birt-Hogg-Dubé

  2011influential citation
• Targeting GLUT1 and the Warburg Effect in Renal Cell Carcinoma by Chemical Synthetic Lethality

  2011cites this paper
• Synthetic lethality-based targets for discovery of new cancer therapeutics.

  2011cites this paper
• Expression of hypoxia‐associated proteins in sporadic medullary thyroid cancer is associated with desmoplastic stroma reaction and lymph node metastasis and may indicate somatic mutations in the VHL gene

  2011cites this paper
• DNA binding characteristics of mithramycin and chromomycin analogues obtained by combinatorial biosynthesis.

  2010cites this paper
• Targeting cancer cells through autophagy for anticancer therapy.

  2010cites this paper
• 4-Pyridylanilinothiazoles that selectively target von Hippel-Lindau deficient renal cell carcinoma cells by inducing autophagic cell death.

  2010cites this paper
• Differential inhibition of restriction enzyme cleavage by chromophore-modified analogues of the antitumour antibiotics mithramycin and chromomycin reveals structure-activity relationships.

  2010cites this paper
• Familial Renal Cell Cancers and Pheochromocytomas

  2010cites this paper
• Effects of Molecularly Targeting Hypoxia in Oncology

  2009cites this paper
• Methodological approaches in application of synthetic lethality screening towards anticancer therapy

  2009cites this paper
• Rational Drug Design: Molecularly Targeted Therapeutics

  2008cites this paper
• Hypoxie und Epithel-Mesenchym-Transition bei der malignen Tumorprogression

  2008cites this paper
• Integrated genomic and pharmacological approaches to identify synthetic lethal genes as cancer therapeutic targets.

  2008cites this paper
• Elevated serum-circulating RNA in patients with conventional renal cell cancer.

  2008cites this paper
• Using molecular biology to develop drugs for renal cell carcinoma

  2008cites this paper
• Targeted therapy for the loss of von Hippel-Lindau in renal cell carcinoma: A novel molecule that induces autophagic cell death

  2008cites this paper
• VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment

  2008cites this paper